Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462486 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 949
- Enrollment target
NCT02462486: Completed Phase 3 study, sponsored by Allergan.
NCT02462486 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 949 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462486, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 949 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Primary Outcome
Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of particip
Interventions
- OTHER Sham Procedure
- DRUG Ranibizumab
- DRUG Abicipar Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2015-06-25 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 3 |
What the finished NCT02462486 record still lists
NCT02462486 is an interventional study that assigns participants to a tested intervention. The registered 949 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT02462486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02462486 about?
NCT02462486 is a clinical study titled "Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration". This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
What is the current status of trial NCT02462486?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 949 participants. The study started on 2015-06-25. Estimated completion is 2019-06-06.
What interventions are being tested in trial NCT02462486?
The interventions under investigation include: Sham Procedure (OTHER), Ranibizumab (DRUG), Abicipar Pegol (DRUG).
Who is sponsoring clinical trial NCT02462486?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02462486's enrollment target sits among peer trials
949 334th of 2000 higher than 1,667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI